BusinessImmune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma PatientsBy Nasdaq OMXOct 16, 2017, 8:16 PM UTC
BusinessInovio Pharmaceuticals Begins Phase 1b/2 Cancer Efficacy Trial Combining Its T-cell Immunotherapy with a PD-L1 Checkpoint Inhibitor in Advanced Bladder CancerBy Nasdaq OMXOct 16, 2017, 11:00 AM UTC
BusinessSelecta Biosciences Announces Upcoming Clinical and Scientific PresentationsBy Nasdaq OMXOct 5, 2017, 12:00 PM UTC
BusinesseFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of eFT508 and Avelumab in Microsatellite Stable Colorectal CancerBy Nasdaq OMXOct 4, 2017, 2:00 PM UTC
BusinessCidara Therapeutics to Present at Two Upcoming ConferencesBy Nasdaq OMXSep 18, 2017, 8:05 PM UTC
BusinessCrownBio’s Integrated Oncology Platform Helps Advance Apogenix’s Promising HERA-GITRL Immunotherapy for NSCLC and Head and Neck CancerBy Nasdaq OMXSep 13, 2017, 2:04 PM UTC
BusinessOmniSeq and LabCorp Sign Exclusive Distribution Agreement and Series B Funding CommitmentBy Nasdaq OMXAug 21, 2017, 12:01 PM UTC
BusinessCidara Provides Corporate Update and Reports Second Quarter 2017 Financial ResultsBy Nasdaq OMXAug 9, 2017, 8:31 PM UTC
